111 results about "DNA - Deoxyribonucleic acid" patented technology

Methods and systems disclosed herein can improve inference of gene expression using cell-free DNA fragments. In an aspect, the present disclosure provides a computer-implemented method for inferring gene expression, the method comprising: obtaining a biological sample from a subject; extracting cell-free deoxyribonucleic acid (cfDNA) from the biological sample, wherein the cfDNA comprises a plurality of cfDNA fragments; performing a sequencing assay on the plurality of cfDNA fragments to generate a plurality of cfDNA sequencing fragments; computer processing the plurality of cfDNA sequencing fragments; and calculating, based at least in part on the computer processing, a gene expression score for a gene in a plurality of genes, wherein the gene expression score indicates a probability of expression or non-expression of the gene in the plurality of genes.

Reported herein is, inter alia, a method for producing a trivalent bispecific antibody, the method comprising the steps of culturing a mammalian cell comprising a deoxyribonucleic acid encoding the trivalent bispecific antibody, and recovering the trivalent bispecific antibody from the cell or culture medium, wherein the deoxyribonucleic acid encoding the trivalent bispecific antibody is stably integrated into the genome of the mammalian cell and comprises in the 5' to 3' direction a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a first light chain, a fourth expression cassette encoding the first light chain, a fifth expression cassette encoding the second heavy chain, a sixth expression cassette encoding the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding the second light chain, wherein the first heavy chain The chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain and a CL domain, the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain, wherein the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site.

96 New PCT-Patent Application based on EP 24 186 635.9 Insempra GmbH Vossius Ref.: AG4141 PCT S3 Abstract The present invention relates to a linear double-stranded deoxyribonucleic acid (dsDNA) molecule comprising one or more Tus protein (Tus) binding site(s) at the 5'-terminus, one or more Lac repressor protein (LacI) binding site(s) at the 3'-terminus, and a segment comprising a DNA sequence of interest (DOI) between said Tus binding site(s) and said LacI binding site(s). The present invention further relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from the linear dsDNA molecule of the invention, and to an expression DNA cassette comprising a promoter, an RBS, a GOI encoding a POI, and one or more LacI binding site(s), wherein said expression cassette does not comprise a terminator sequence between the 3´ end of said GOI and said one or more LacI binding site(s). The present invention also relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from said expression cassette. The present invention further relates to method of protecting a linear deoxyribonucleic acid (DNA) molecule from exonuclease degradation by adding one or more Tus binding site(s) at the first terminus of the DNA molecule and adding one or more LacI binding site(s) at the other terminus of the DNA molecule. The present invention further relates to a method of synthesizing a protein of interest (POI) in a cell- free protein synthesis (CFPS) reaction mixture by using the (ds)DNA and / or RNA molecules of the invention, and also to a cell-free biological system or CFPS reaction mixture comprising the (ds)DNA, expression cassette and / or RNA molecules of the invention.

The invention provides an invasive species identification method and device based on deep learning and DNA storage and electronic equipment, and relates to the technical field of invasive organism prevention and control, and the method comprises the steps: obtaining a to-be-identified invasive species image, and generating a first DNA sequence of a to-be-identified invasive species in the invasive species image through a deoxyribonucleic acid DNA encoder; obtaining a plurality of second DNA sequences to be hybridized from the invasive species database, and obtaining the hybridization yield of the first DNA sequence and each second DNA sequence by using a hybridization yield predictor; and determining the species category corresponding to the DNA sequence with the highest hybridization yield as the species category of the invasive species to be identified. According to the method provided by the invention, the strong feature extraction capability of deep learning is combined with the advantages of ultrahigh density and ultra-long stability of DNA as a data storage medium, so that end-to-end mapping and recognition from a species image to an exclusive DNA sequence thereof are realized.

The invention relates to preparation and application of a desoxyribonucleic acid and desoxyribonucleic acid derivative transdermal delivery system, and belongs to the technical field of biological medicine and skin care products. Desoxyribonucleic acid and derivatives thereof have the effects of resisting aging, repairing and the like, but are difficult to penetrate through a skin barrier due to large molecular weight and strong polarity. According to the invention, hydroxyethyl chitosan, desoxyribonucleic acid and derivatives thereof are combined through electrostatic interaction to form the nano-composite. The compound is small in particle size and can promote transdermal absorption through hair follicle or cuticle gaps. The preparation method is simple, does not need an auxiliary reagent, and comprises the step of mixing a hydroxyethyl chitosan solution and a deoxyribonucleic acid derivative solution. Experiments show that the compound significantly enhances the transdermal efficiency, and has the effects of promoting cell repair and proliferation and resisting inflammation. The composition can be used for skin care products, and is high in safety and wide in application prospect.

The present invention relates to methods for producing a protected deoxyribonucleic acid (DNA) product with enhanced resistance to nuclease digestion. The methods comprise digesting a double-stranded DNA molecule with an endonuclease to generate a digested double-stranded DNA molecule comprising a first strand and a second strand, wherein the first strand has a 5' overhang; and extending the second strand 5' to 3' using a polymerase in the presence of one or more nuclease-resistant deoxynucleotide triphosphates to generate the protected DNA product, wherein the protected DNA product comprises an extended second strand comprising at least one nuclease-resistant nucleotide incorporated into the extended second strand by the polymerase using the 5' overhang of the first strand as template. Also provided are protected DNA products and uses thereof.

Disclosed herein are methods for processing a cell-free sample of a subject, comprising, providing said cell-free sample of said subject, wherein said cell-free sample comprises a plurality of nucleic acid molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of complementary deoxyribonucleic acid (cDNA) molecules or derivatives thereof, and sequencing said plurality of cDNA molecules or derivatives thereof. Further disclosed herein are systems, comprising a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to provide a cell-free sample of a subject, wherein said cell-free sample comprises a plurality of nucleic acid molecules, subject said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of complementary deoxyribonucleic acid (cDNA) molecules or derivatives thereof, and sequence said plurality of cDNA molecules or derivatives thereof.

The present application relates to a deoxyribonuclease mutant and its application in preparing PDRN. The amino acid sequence of the deoxyribonuclease mutant is shown as SEQ ID NO. 1, and the nucleotide sequence of the encoding gene is shown as SEQ ID NO. 2. The present application also provides the application of the deoxyribonuclease mutant and / or the encoding gene of the deoxyribonuclease mutant in preparing PDRN, and the specific application method. The present application is based on the deoxyribonuclease expressed by the DNASE1 gene of bovine pancreas tissue, and the amino acids at positions 69, 132 and 215 are selected for iterative saturation mutation. Compared with the wild-type enzyme, the enzyme activity of the deoxyribonuclease mutant A69H-S132R-Q215C is increased by 2.15 times, reaching 4.1x10 6 U / mL, and the DNA extraction rate of salmon PDRN prepared by using the mutant enzyme prepared by the present application is 15.2%, the DNA content is 99.1%, and the molecular weight is 1.05 million Daltons, which is significantly improved compared with the wild-type enzyme, and the PDRN in this molecular weight range has more significant biological activity.

The application provides a kit for extracting RNA and application thereof. In the application, deoxyribonuclease (DNase) is used for DNA digestion in the process of magnetic bead extraction. The reaction environment can meet the optimal reaction environment requirement of the deoxyribonuclease (DNase), and at the same time, a hydrophobic environment is provided when the magnetic beads are adsorbed, so as to ensure the yield of nucleic acid. In addition, an emulsion of an oil is added to increase the total volume during the extraction operation, so as to facilitate the convenience of automatic extraction operation of the instrument. The extracted RNA has high yield and high purity, and the method can easily realize automatic extraction of the instrument. The requirement of extracting high-purity RNA quickly and conveniently in the process of clinical practical application is solved, the difficulty and cost of extracting high-purity RNA are greatly reduced, and the extracted RNA can be well adapted to subsequent RT-PCR and RNA-seq application.

The invention discloses a multi-channel high-precision liquid injection device for DNA synthesis and a method thereof, and relates to the field of deoxyribonucleic acid synthesis equipment.The multi-channel high-precision liquid injection device comprises a device shell; the movable mounting box is arranged at the bottom in the device shell in a sliding mode, a mounting groove is formed in the top of the movable mounting box, a clamping plate is arranged at the top in the mounting groove, and a plurality of combined columns are arranged on the clamping plate; and the cover plate is rotationally arranged on the fixed plate through a connecting rod. According to the invention, through the modularized liquid injection head assembly and the flexibly configured sequence identification system, the device can carry out multiple groups of different DNA synthesis operations at the same time, so that the synthesis flux and flexibility are obviously improved; by means of the driving and guiding mechanism and the electromagnetic coupling technology, efficient and accurate positioning of the liquid beating head in a two-dimensional plane is achieved, and the contradiction between multi-channel processing and positioning accuracy is solved.

The present invention relates to a functionalized artificial cell based on a composite coacervate, preparation and application thereof, and relates to the field of biomedicine technology. The preparation method is as follows: a positively charged solution and a negatively charged solution are mixed, the positively charged solution being a polylysine solution or an ε-polylysine hydrochloride solution, and the negatively charged solution being a deoxyribonucleic acid solution; a coacervate droplet suspension containing functional components is obtained by liquid-liquid phase separation; phospholipids and PEGylated phospholipids are dissolved in an organic solvent and then subjected to vacuum rotary evaporation until the organic solvent evaporates to obtain a lipid membrane; the coacervate droplet suspension is added to the lipid membrane for hydration until the lipid membrane is completely dissolved, thereby obtaining a functionalized artificial cell; at least one of the positively charged solution, the negatively charged solution and the phospholipid solution contains a functional component. The functionalized artificial cell based on the composite coacervate constructed by the present invention has a cell membrane-like and cytoplasm-like structure, and has good physiological stability and biocompatibility.

Methods for obtaining a target median deoxyribonucleic acid (DNA) insert size utilizes several solid-phase reversible immobilization (SPRI) bead solutions. At different steps of the method workflows, different ratios of the SPRI bead solution to DNA solution are utilized. Each method includes back-to-back DNA fragment removal / retention steps, where different ratios of the SPRI bead solution to DNA solution are utilized in the back-to-back steps.

A treatment method for room-temperature preservation of cell deoxyribonucleic acid, comprising the following steps: placing cells in a preservation tube containing a cell deoxyribonucleic acid preservation reagent, and performing freezing preservation at a temperature of -20°C to -80°C; and then performing thawing, and drying the cell deoxyribonucleic acid preservation reagent within the preservation tube to eliminate moisture.

Disclosed are single-stranded deoxyribonucleic acid (DNA) molecules comprising at least one nucleic acid sequence of interest flanked with a first at least one stem-loop structure, methods of making and methods of use for delivery and expression of a transgene in a host cell.

The invention provides a method for producing a partially closed deoxyribonucleic acid (DNA) product, wherein the method comprises: (a) contacting a double-stranded DNA molecule with an endonuclease a

The present disclosure relates to a method of inhibiting nuclease activity in a biological sample. In accordance with certain embodiments of the present disclosure, the method comprises mixing a biological sample with a metal-chelating agent complex. The present disclosure also discloses a method of isolating a cell nucleus from a cell in a biological sample by using the metal-chelating agent complex, and a method of adding a deoxyribonucleotide to the 3'terminal of a deoxyribonucleic acid.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

Herein is reported a method for producing C-terminally biotinylated FcRn comprising the steps of cultivating a mammalian cell comprising a deoxyribonucleic acid encoding FcRn and E. coli biotin-[acetyl-CoA-carboxylase] ligase (BirA) in a biotin containing medium, and recovering C-terminally biotinylated FcRn from the cell or the cultivation medium, wherein the deoxyribonucleic acid encoding FcRn and E. coli BirA is stably integrated into the genome of the mammalian cell and comprises in 5′- to 3′-direction a first expression cassette encoding class I major histocompatibility complex-like protein (α-FcRn) comprising a HisAvi-tag at the C-terminus, a second expression cassette encoding β2-microglobulin (β2m), a third expression cassette encoding class I major histocompatibility complex-like protein (α-FcRn) comprising a HisAvi-tag at the C-terminus, a fourth expression cassette encoding β2-microglobulin (β2m), and a fifth expression cassette encoding E. coli biotin-[acetyl-CoA-carboxylase] ligase.

A system includes a hydration module configured to rehydrate lyophilized reagents for a rolling circle amplification reaction. The system also includes a deoxyribonucleic acid (DNA) amplification module configured to generate a DNA product from a DNA template and rehydrated reagents utilizing a rolling circle amplification reaction.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

The present disclosure relates generally to devices and methods for rapid and accurate diagnosis of single nucleotide polymorphisms. According to one or more embodiments, a system for identifying a single nucleotide polymorphism (SNP) comprises an oligonucleotide primer having a SNP recognition sequence, a fluorophore conjugated to the oligonucleotide primer at a conjugation site to form a fluorophore-conjugated oligonucleotide primer, a polymerase for extending the oligonucleotide primer to form a double-stranded deoxyribonucleic acid (DNA) amplicon upon binding to an oligonucleotide strand having a complementary sequence to the oligonucleotide primer, and wherein the fluorophore-conjugated oligonucleotide primer is the only primer in the system such that the fluorophore emits a fluorescent signal only when the fluorophore-conjugated oligonucleotide primer binds to a sequence specifically complementary to the SNP recognition sequence.

In an example deoxyribonucleic acid (DNA) enrichment method, a DNA sample containing a region of interest is tagmented using bead-linked transposomes. This generates bead-linked DNA fragments. A Cas nuclease / RNA guide complex is introduced to the bead-linked DNA fragments, which cleaves DNA fragments containing the region of interest. The Cas nuclease / RNA guide complex is denatured, which releases the DNA fragments containing the region of interest from the bead- linked transposomes. The DNA fragments containing the region of interest are introduced into a flow cell containing surface-bound transposomes. Other enrichment methods are also disclosed.

A system may receive DNA sequencing data for a subject, the DNA sequencing data comprising a plurality of variants, wherein the plurality of variants comprise a plurality of copy number variants (CNVs). A system may identify a cytoband variant or a chromosomal variant among the plurality of CNVs. A system may detect a hematopoietic neoplasm in the subject based, at least in part, on the plurality of variants including the cytoband variant or the chromosomal variant.

Synthetic molecular tags are placed on an item at various points in a supply chain to create a molecular record of movement through the supply chain. Associations between each unique synthetic molecular tag and individual locations in the supply chain are stored in an electronic record which may be maintained in the cloud. The synthetic molecular tags are collected from the item and sequenced to determine movement of the item through the supply chain by reference to the electronic record. The synthetic molecular tags can be used for identifying recalled items based on locations in the supply chain associated with a recall. The synthetic molecular tags may be polynucleotides such as deoxyribose nucleic acid (DNA). The item may be any type of item including food.

The invention discloses application of a CGAS-STING signal channel inhibitor in preparation of a medicine for preventing and treating hepatic ischemia-reperfusion injury, and relates to the technical field of biological medicine. According to the application, a cGAS-STING signal channel in macrophages is inhibited by using a cGAS inhibitor or an STING inhibitor, activation of double-stranded deoxyribonucleic acid released by a neutrophile granulocyte extracellular trapping net on a DNA induction channel is blocked, and the M1 type polarization level of the macrophages is reduced. The traditional Chinese medicine composition can effectively relieve liver inflammatory response and cell apoptosis, and a new path is provided for preventing and treating acute liver injury after liver transplantation or liver resection.

Linear DNA with improved resistance against exonucleases and methods for its production. The present invention relates to methods for producing a linear deoxyribonucleic acid (DNA) product (e.g., a closed linear DNA product) with improved resistance to nuclease digestion. The present invention relates to methods comprising the steps of: (a) contacting a double-stranded DNA molecule with an endonuclease, a ligase, and first and second terminal adaptor molecules and intermediate adaptor molecules to form a single contiguous aqueous volume; and (b) incubating the single contiguous aqueous volume to generate a linear DNA product (e.g., a closed linear DNA product). The present invention also relates to linear deoxyribonucleic acid (DNA) products (e.g., a closed linear DNA product) with improved resistance to nuclease digestion and uses thereof.

The invention discloses application of desoxyribonucleic acid-poly-L-lysine composite hydrogel in redistribution of endogenous exosomes and treatment of myocardial infarction, and the desoxyribonucleic acid-poly-L-lysine composite hydrogel comprises a DNA (deoxyribonucleic acid) skeleton and poly-L-lysine wrapping the DNA skeleton, the DNA skeleton contains a nucleic acid aptamer targeting exosome surface protein, and the desoxyribonucleic acid-poly-L-lysine composite hydrogel is used for capturing and releasing endogenous exosomes. According to the invention, the injectable desoxyribonucleic acid-poly-L-lysine composite hydrogel is used for treating myocardial infarction, and targeted enrichment and controllable release of endogenous exosomes are realized through the unique molecular design of the desoxyribonucleic acid-poly-L-lysine composite hydrogel; important breakthrough is achieved in the aspects of targeting, controllability, safety, clinical transformation and the like, and a brand new solution is provided for myocardial infarction treatment.

Disclosed is a method of determining whether a human subject is not a carrier of spinal muscular atrophy (SMA). This method includes the steps of (i) collecting a genomic deoxyribonucleic acid (DNA) sample from a human subject; (ii) screening the genomic DNA sample to determine the human subject's copy number of survival of motor neuron 1 (SMN1) gene and whether one of the copies of the SMN1 gene is positive for a polymorphism associated with non-carriers of SMA having two copies of the SMN1 gene; and (iii) determining the human subject as not a carrier of SMA if the human subject includes two copies of the SMN1 gene with one of those copies being positive for the polymorphism. Also disclosed is a method of determining whether an individual has a decreased risk of being a carrier of spinal muscular atrophy (SMA), where the individual is identified to have a decreased risk of being a carrier of SMA when the individual has two copies of the SMN1 gene with one of those copies being positive for the polymorphism.

The present disclosure relates generally to devices and methods for rapidly and accurately diagnosing single-nucleotide polymorphisms. According to one or more embodiments, a system for identifying a single-nucleotide polymorphism (SNP) includes an oligonucleotide primer with a SNP recognition sequence, a fluorophore conjugated to the oligonucleotide primer at a conjugation site to form a fluorophore-conjugated oligonucleotide primer, a polymerase enzyme to extend the oligonucleotide primer upon binding to an oligonucleotide strand with a complimentary sequence to the oligonucleotide primer, forming a double stranded deoxyribonucleic acid (DNA) amplicon, and wherein the fluorophore-conjugated oligonucleotide primer is a sole primer in the system, such that the fluorophore only emits a fluorescent signal when the fluorophore-conjugated oligonucleotide primer binds to a sequence specifically complementary to the SNP recognition sequence.